Brief: Alkermes Presents First Clinical Data For Orexin 2 Receptor Agonist Alks 2680

Alkermes

23/10/2023 14:08

Oct 23 (Reuters) - Alkermes Plc  ALKS.O :
    * ALKERMES PRESENTS FIRST CLINICAL DATA FOR OREXIN 2
RECEPTOR
AGONIST ALKS 2680 AT WORLD SLEEP CONGRESS
    * ALKERMES PLC - INITIAL ALKS 2680 DATA DEMONSTRATED
DOSE-DEPENDENT, SIGNIFICANTLY IMPROVED SLEEP LATENCY COMPARED TO
PLACEBO IN NARCOLEPSY TYPE 1
    * ALKERMES PLC - ALKS 2680 WAS GENERALLY WELL TOLERATED AT
ALL
DOSES TESTED
    * ALKERMES PLC - PHARMACOKINETIC PROFILE OF ALKS 2680
SUPPORTS
ONCE-DAILY DOSING AND MIMICS NATURAL SLEEP/WAKE CYCLE
    * ALKERMES PLC - CONSISTENT, DOSE-DEPENDENT EFFECTS ENABLE
DOSE
SELECTION FOR EVALUATION IN PLANNED PHASE 2 STUDY
    * ALKERMES PLC - DRUG-RELATED ADVERSE EVENTS (AES) WERE SEEN
ONLY
AT 8 MG DOSE AND WERE MILD IN SEVERITY
    * ALKERMES PLC - THERE WERE NO SERIOUS AES OR AES LEADING TO
DISCONTINUATION
    * ALKERMES - THERE WERE NO CLINICALLY MEANINGFUL,
TREATMENT-EMERGENT CHANGES IN HEPATIC, RENAL PARAMETERS, VITAL
SIGNS, OR ELECTROCARDIOGRAM PARAMETERS
    * ALKERMES PLC - PLAN TO INITIATE OUR PHASE 2 STUDY OF ALKS
2680,
IN FIRST HALF OF 2024

Source text for Eikon:  ID:nPn5Jgwja 
Further company coverage:  ALKS.O 

 ((Reuters.Briefs@thomsonreuters.com;))